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Abstract Prostaeyclin, one of the major prostanoids generated 
in adipose tissue, has been previously described as an autocrine/ 
paracrine adipogenie effector, acting, in preadipose cells, by 
means of cAMP and free Ca 2+ as cell surface receptor-mediated 
messengers. The present study presents evidence for the first time 
that its stable analogue, carbaprostacyclin, is unique among 
prostanoids in regulating the expression of two differentiation- 
dependent genes in preadipose and adipose cells in a way distinct 
from that elicited by its cell surface receptor. This regulation is 
likely mediated by some member(s) of the peroxisome prolif- 
erator-activated receptor family and suggests that prostacyclin 
behaves as an intracrine effector of adipose cell differentiation. 
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1. Introduction 
The terminal differentiation of preadipose into adipose cells 
is triggered by a few adipogenic hormones [1]. Among pros- 
tanoids, a potent and specific adipogenic role has been delin- 
eated for carbaprostacyclin (cPGI2) and other stable ana- 
logues of prostacyclin (PGI2) [2-4], which is one of the major 
metabolites of arachidonic acid in both preadipose and adi- 
pose cells [5-8]. On a short-term basis both PGI2 and its 
stable analogue cPGI2 play a similar dual role in eliciting 
elevation of intracellular cAMP and free Ca 2÷ [9,10] and, in 
addition, are equally active on a long-term basis in triggering 
terminal differentiation of preadipose to adipose cells ([2] and 
J. Aubert et al., unpublished results), cPGI2 has indeed been 
shown to specifically promote terminal differentiation ot 
only of preadipocytes from clonal lines but also that of adi- 
pose precursor cells isolated from murine or human adipose 
tissue and maintained in primary culture under chemically 
defined, serum-free conditions [4,11]. Moreover, PGI~ behaves 
as an autocrine/paracrine effector of adipose cell differentia- 
tion in vitro by means of binding to its cell surface receptor 
[3,4,12,13]. Recent studies, using adipose tissue explants or in 
situ microdialysis of fat pads, have shown that this prosta- 
glandin (PG), known to be present in the interstitial f uid of 
adipose tissue [14], is able to recruit adipose precursor cells 
and to trigger the formation of new fat cells (C. Darimont et 
al., unpublished results). 
After binding to their cell surface receptors, the ability of 
PGI2 and cPGI2 to activate adenylate cyclase via a Gs-de- 
pendent mechanism in preadipose but not in adipose cells 
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[15], coupled to their ability to increase intracellular free 
Ca 2+ [4,14], was thought o account for their potent and spe- 
cific adipogenic property. Quite recently, 15-deoxy-A 12'14 
PGJ2, a PGJ2 metabolite, has been shown to bind to peroxi- 
some proliferator-activated r ceptor 7 (PPART), a member of 
the nuclear eceptor superfamily of ligand-activated transcrip- 
tion factors, and to promote adipose cell differentiation [16- 
18]. So far, no evidence of synthesis of 15-deoxy-A 12,14 PGJ2 
has been given in either preadipose or adipose cells, raising 
concern about the physiological significance of this finding. 
Furthermore, PPARa and PPAR& also reported to be pres- 
ent in preadipose and adipose cells, but more ubiquitously 
expressed than PPAR7 [19], have also been shown to be acti- 
vated by various prostanoids [17,18,20--22]. In those studies, 
the activation potency of a given effector was depending on 
the nature of the recipient cell and on that of the combination 
of expression vector and reporter gene. To add further com- 
plications cPGI2, reported to be an activator of all three 
PPAR isoforms in transactivation assays, exhibited an adipo- 
genic activity in NIH fibroblasts stably transfected with 
PPARc~ and PPAR 7 but not with PPAR8 [22]. Altogether, 
these results strongly suggest hat activators modulate the 
availability and/or the formation of intracellular ligands. As 
both events may differ in a particular cellular context, studies 
using model target cells, i.e. preadipose and adipose cells from 
clonal lines, are indeed required. The validity of using such 
cells has been previously shown, since they behave as authen- 
tic precursor cells of adipocytes both in vitro and in vivo 
[23,24], similarly to precursor cells isolated from adipose tis- 
sue [251. 
These various observations have prompted us to investi- 
gate, in Ob1771 and 3T3-F442A preadipose and adipose cells, 
the regulation by cPGI2 of the expression of two genes al- 
ready shown to respond to long-chain atural or non-metab- 
olized fatty acids as well as peroxisome proliferators, i.e. genes 
encoding for angiotensinogen (AT) (I. Safonova et al., sub- 
mitted for publication) and adipocyte fatty acid binding pro- 
tein (a-FABP) [26,27], the promoter region of which was 
known to contain a peroxisome proliferator response lement 
[28]. The results reported herein show that cPGI2 is unique 
among PGs to activate the expression of AT and a-FABP 
genes in these cells and that its effect is distinct from that 
taking place via its cell surface receptor. 
2. Materials and methods 
2.1. Cell culture 
Cells of Ob1771 [29] and 3T3-F442A [30] clonal ines were plated at 
a density of 2× 103 cells per cm 2 and grown in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 8% fetal bovine serum, 
200 units/ml of penicillin, 50 ~g/ml of streptomycin, 33 ~tM biotin, 
and 17 ~tM pantothenate (referred to as standard medium). Under 
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Fig. 1. Accumulation of AT and a-FABP mRNAs in Ob1771 preadipose cells exposed to various prostaglandins or to cAMP and Ca 2+ elevat- 
ing drugs. One-day post-confluent preadipose cells cultured as described in Section 2 were maintained for 24 h in IT medium alone (control) or 
supplemented either with increasing concentrations of cPGI2 as indicated, or with various prostaglandins (all present at a concentration of 
1 laM) or with a mixture of 10/aM forskolin and 0.1 /aM ionomycin (Fsk+iono). RNAs were then extracted and analyzed (20/ag/lane) as de- 
scribed in Section 2. The intensities of the signals were normalized to those of I~-actin and expressed by taking as 100% the maximal response 
obtained for each probe. The data are the means + S.E.M. of values obtained in three separate xperiments. Black columns correspond to AT 
and white columns to a-FABP mRNA. 
these conditions, confluence (day 0) was reached within 5 days. Unless 
otherwise stated 1 day post-confluent cells, i.e. lipid-free preadipose 
cells known to express early markers of differentiation only [1], were 
used. Triacylglycerol-containing differentiated cells, able to express 
late markers of differentiation as well [1], were also used in some 
experiments. These latter were obtained by feeding confluent 
Ob1771 as well as 3T3-F442A cells chronically with standard medium 
described above containing 17 nM bovine insulin plus 2 nM triio- 
dothyronine, and supplemented with 10 nM dexamethasone and 100 
/aM 3-isobutyl-l-methylxanthine during the first 3 days. Media were 
changed every other day. 
For experimental purposes, both undifferentiated preadipose cells 
and differentiated adipose cells were transferred to a serum-free med- 
ium consisting of DMEM supplemented with 850 nM bovine insulin 
and 10/ag/ml human transferrin. This serum-free, chemically defined 
medium (referred to as IT medium) was supplemented or not with the 
various effectors and for periods of time indicated in the legend of 
figures. 
2.2. RNA analysis 
RNAs were prepared by the guanidium thiocyanate t chnique [31]. 
For Northern blot analysis, 20 /ag total RNAs were separated by 
electrophoresis on 1.2% (w/v) agarose gel containing 1.1 M formalde- 
hyde and transferred onto a Hybond-N ÷ membrane (Amersham, 
France). Hybridizations were performed for 24 h at 65°C in 0.5 M 
phosphate buffer, pH 7.2, containing 5% SDS and 106 cprrdml of 
randomly primed 32p-labeled cDNA probes. The autoradiographs 
were quantitated using a Fujix phosphorimager. All results were nor- 
malized to 13-actin signals. 
2.3. Angiotensinogen protein assay 
Ob1771 and 3T3-F442A cells, grown and previously induced to 
differentiate as described above (2 cm 2 culture wells), were thoroughly 
washed three times (twice rapidly and once for 1 h) with IT medium. 
They were then incubated at 37°C for 24 h in 1 ml of fresh IT medium 
containing or not an additional effector. The culture medium was 
collected in the presence of 1% bovine serum albumin and a cocktail 
of anti-proteolytic agents including 1 mM paramethylsulfonylfluoride, 
5 mM EDTA, 1 mM hydroxyquinoline and 10 /aM captopril. The 
amount of AT present in suitable aliquots of culture medium was 
determined, after its total conversion to angiotensin I (AngI) in the 
presence of an excess of mouse renin, by measuring AngI with a 
radioimmunoassay [32]. Renin from mouse submaxillary gland was 
prepared according to the method of Jacobsen and Poulsen [33]. 
2.4. Materials 
Culture media were obtained from Gibco (Cergy-Pontoise, France) 
and fetal bovine serum from Seromed (Berlin, Germany). All other 
cell culture products were obtained as previously reported [9,10]. [c~- 
z2P]dCTP, random priming kit, Hybond membranes and products 
used for the radioimmunoassay of AT were purchased from Amer- 
sham (Les Ulis, France). Restriction enzymes were from Eurogentec 
(Seraing, Belgium). Actinomycin D, cycloheximide, dexamethasone, 
forskolin and ionomycin were purchased from Sigma Chimie (Saint 
Quentin Fallavier, France). All prostanoids were products from Cay- 
man Chemicals (SpiBio, Massy, France). RU 38486 was a kind gift 
from Roussel Uclaf. The sources of the various cDNAs used in this 
study are acknowledged in the corresponding section. 
3. Results 
As shown in Fig. 1, Ob1771 preadipose cells, maintained in 
IT medium, were able to respond specifically, rapidly (within 
24 h) and dose-dependently to cPGI2 in accumulating high 
levels of AT and a-FABP mRNAs.  Apart  from PGF2a and 
PGD2, which slightly enhanced mainly the a-FABP signal, 
other PGs such as PGE2, PGJ2, PGE1, 6-keto-PGE1 and 6- 
keto-PGFla,  when present at 1 ~tM, were unable to exert a 
significant effect on the level of both AT and a-FABP mRNA.  
The metabolites of PGJ2, AI~-PGJ2 and 15-deoxy-Aa2,14-pGJ2, 
were also found to be inactive (not shown). It is striking that 
PGE1 and 6-keto-PGE1 were inactive despite their binding to 
the same cell surface receptor as PGI2 [34,35], and their ability 
to alter intracellular cAMP and free calcium levels [10] and to 
induce the terminal differentiation of Ob 1771 preadipose cells, 
a lthough to a lower extent than cPGI2 [2]. Moreover, simul- 
taneous exposure to an adenylate cyclase agonist (forskolin) 
and a calcium ionophore (ionomycin), which are able to mira- 







Fig. 2. Effect of actinomycin D and cycloheximide on AT and a- 
FABP mRNA levels in Ob1771 preadipose cells exposed to cPGI2. 
One-day post-confluent preadipose cells were maintained for 20 h in 
IT medium alone (control) or supplemented with 1 I.tM cPGI2, 2 gg/ 
ml actinomycin D (Act D), 1 gg/ml cycloheximide (Cyclo) or a 
combination of cPGI2 and these latter compounds (cPGI2+Act D 
and cPGI2+Cyclo, respectively). 15 h later, RNAs were extracted 
and analyzed (20 gg/lane) as described in Section 2. The results are 
representative of three separate experiments. 
of cPGIz with the glucocorticoid nuclear eceptor, if any, had 
to be excluded. Northern blots presented in Fig. 3 show 
clearly that the glucocorticoid antagonist RU 38486 complete- 
ly abolished the increase in AT and a-FABP mRNAs in- 
duced by a maximally effective concentration of dexametha- 
sone, whereas it had no effect on that induced by cPGI2. 
These results demonstrate hat AT and a-FABP gene expres- 
sion were independently regulated by glucocorticoids and 
cPGI2. Furthermore, in the light of the small increase in a- 
FABP mRNA elicited by 0.1 gM dexamethasone, these results 
would indicate a preferential regulation of a-FABP gene ex- 
pression by cPGI2 as compared to glucocorticoids. 
The ability of PGI2 and cPGI2 to increase intracellular 
cAMP has been shown to affect cells at the preadipose state 
exclusively [15], strongly suggesting that cell surface receptors 
and/or the coupling mechanism that mediate this biological 
response disappeared uring the differentiation process. 
Thus the regulation of AT and a-FABP gene expression as 
well as AT secretion, if any, was studied in differentiated 
Ob1771 and 3T3-F442A adipose cells (Fig. 4). For that pur- 
pose, prior decrease of both mRNAs was obtained by a 20 h 
preincubation period in IT medium. The results of Fig. 4A 
show that differentiated cells responded to cPGI2 by an in- 






ic the intracellular signals triggered by cPGI2 after binding 
to its cell surface receptor [4] and also to lead to terminal 
differentiation of preadipose to adipose cells, did not change 
AT or a-FABP mRNA levels. Therefore, the specific stimulat- 
ing effect of cPGI2 on AT and a-FABP genes appeared to be 
mediated by a mechanism distinct from the cell surface recep- 
tor signalling pathway. 
As shown in Fig. 2, the accumulation of AT and a-FABP 
mRNAs in preadipose cells exposed to 1 gM cPGI2 for 15 h 
was abolished in the presence of actinomycin D or cyclohex- 
imide, suggesting that cPGI2 regulates the expression of these 
genes by means of transcriptional ctivation and requires de 
novo protein synthesis. 
Besides arachidonic acid, PGI2 and PGI2 analogues, gluco- 
corticoids are the only hormones able to trigger terminal dif- 
ferentiation of Ob1771 preadipose cells under serum-free cul- 
ture conditions [1,3,12]. These hormones are also able to 
activate transcription of several genes expressed uring the 
differentiation process, including AT (J. Aubert et al., unpub- 




Fig. 3. Differential modulation of AT and a-FABP mRNA accumu- 
lation by dexamethasone and cPGI2 in Ob1771 preadipose c lls. 
One-day post-confluent preadipose cells were maintained for 24 h in 
IT medium alone (control) or supplemented with 0.1 gM dexa- 
methasone (Dex), 1 gM cPGI2, 0.1 gM RU 38486 (RU) or a com- 
bination of this latter compound with dexamethasone or cPGI2 
(Dex+RU and cPGI2+RU). RNAs were then extracted and ana- 
lyzed (20 gg/lane) as described in Section 2. The results are repre- 
sentative of three separate experiments. 
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Fig. 4. Induction of AT and a-FABP mRNA and AT secretion i Ob1771 and 3T3-F442A adipose cells by cPGI2. Ob1771 or 3T3-F442A cells, 
grown and maintained under the culture conditions described to induce their differentiation (see Section 2) were transferred to IT medium for 
20 h. They were then fed with fresh IT medium that was supplemented with increasing concentrations of cPGI2 as indicated for Ob1771 cells 
in A or with either 1 laM cPGI2 or PGE1 for Ob1771 and 3T3-442A adipocytes in B. 24 h later, RNAs were extracted and analyzed (20 /.tg/ 
lane). The result of this analysis representative of three separate experiments is shown in A. The amounts of AT, present in the culture medium 
of adipocytes exposed uring 24 h to IT medium alone or supplemented with either 1 oM cPGI2 or PGE1, measured by radioimmunoassay 
(see Section 2) are shown in B. The data are the means + S.E.M. of values obtained in three separate experiments. 
manner. Furthermore, in agreement with the fact that AT 
mRNA expression is accompanied by AT synthesis and secre- 
tion (J. Aubert et al., unpublished results), 1 gM cPGI2 was 
also able to give rise to a 2.5-fold increase in the amount of 
AT present in the culture medium of both Ob1771 and 3T3- 
F442A differentiated cells (Fig. 4B). Once again, PGE1 failed 
to mimic cPGI~ in enhancing AT secretion into the culture 
medium. 
4. Discuss ion 
Both PGI2 and the stable prostanoid cPGI2, like glucocor- 
ticoids, are known to control on a long-term basis the termi- 
nal differentiation f growth-arrested Ob1771 preadipose cells 
([2] and J. Aubert et al., unpublished results). The regulation 
of AT and a-FABP gene expression by cPGI2 on a medium- 
term basis appears distinct from the differentiation process per 
se as it occurs many days earlier than terminal differentiation 
and under culture conditions which are insufficient to induce 
terminal differentiation [1,3,12]. This regulation is rather spe- 
cific as cPGI2 appears to be the sole active PG and it is not 
confined to Ob1771 cells since it occurs also in 3T3-F442A 
cells. It is unlikely that this specific effect might be due to the 
stability of cPGI2 as compared to that of other PGs. First, 
stable PGE1, PGE2, PGF2a, 6-keto-PGFla nd 6-keto-PGE1 
are inefficient in inducing AT and a-FABP gene expression 
(Fig. 1). Second PGI2, which shares with PGD2 and PGJz a 
poor chemical stability, is the only prostanoid able to trigger 
the terminal differentiation f preadipose to adipose cells dur- 
ing which AT and a-FABP genes are induced ([2] and J. 
Aubert et al., unpublished results). 
The salient feature of this regulation by cPGI2 is its clear 
dissociation from events controlled by the 'classical' cell sur- 
face receptor of PGI2 (IP receptor) [36,37]. Three arguments 
are in favor of this conclusion: (i) the inability of two PGs to 
mimic the cPGI2-induced AT and a-FABP gene expression, 
namely PGE1 and 6-keto-PGE1, despite the fact that both are 
ligands of the IP receptor [34,35], alter intracellular cAMP 
and free Ca z+ levels [4,10] and exhibit weak adipogenic prop- 
erties [2], (ii) the inability of forskolin and ionomycin to con- 
trol AT and a-FABP gene expression despite their ability to 
induce terminal differentiation [4] and (iii) the persistence of 
the regulation of AT and a-FABP gene expression by cPGI2 
in differentiated cells, once they become unable to generate 
cAMP upon exposure to this prostanoid [15]. In this latter 
case, a possible response due to undifferentiated cells still 
remaining in the population can be ruled out since AT secre- 
tion is very weak, if any, in preadipose cells (I. Safonova et 
al., submitted for publication). 
Among hypotheses to explain the gene effect of cPGI2, the 
implication of other plasma membrane prostanoid receptors i
rather unlikely. Both FP and DP receptor can be excluded 
since their most specific ligands, PGF2a and PGD2 respec- 
tively, fail to activate AT and a-FABP gene expression. One 
could argue that the EP1 receptor isoform is implicated as it is 
also able to bind iloprost, a stable analogue of PGI2 [36]. This 
hypothesis can also be excluded as its most specific ligands 
(PGs of the E series, i.e. PGE1 and PGE2) are inactive at the 
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gene level. This conclusion can be extended for the same rea- 
son to other characterized EP receptor isoforms (EP2 and 
EP3 receptors). 
Although the implication of plasma membrane receptors 
different from known prostanoid receptors cannot be ruled 
out, it is proposed that the effect of cPGI2 at the gene level 
is mediated by members of the PPAR family. This proposal is 
supported by several observations: (i) AT and a-FABP gene 
expression is regulated in preadipose cells by non-metaboliz- 
able and natural ong-chain fatty acids, through activation of 
PPAR 8 and/or PPAR 7 which are respectively present at high 
and low levels in Ob1771 preadipose cells and which both 
accumulate in differentiated adipose cells ([26,27] and I. Safo- 
nova et al., submitted for publication), (ii) PGI2 analogues, 
especially cPGIe, have been reported in transactivation assays 
to activate not only PPARt~ [21] but all PPAR isoforms in the 
range of concentrations required in the present study (0.025- 
10 gM) [21] and (iii) PPAR activators, including prostanoids 
and cPGI2, are able to induce adipogenesis in transfected 
fibroblasts overexpressing PPARct or PPAR7 within the 
same range of concentrations (0.5-10 gM) [17,18,20,22]. 
It should be recalled that, besides PGE2 and trace levels of 
PGF2~, PGI2 is the only arachidonic acid metabolite whose 
production has been clearly demonstrated to occur in preadi- 
pose and adipose cells both in vitro [5-8] and in vivo [14]. 
Since neither PGE2 nor PGF2a was shown to play a direct 
role at the gene level as well as in adipogenesis [2,4,10,15], it 
appears that PGI2 is the most likely prostanoid candidate to 
regulate adipose cell gene expression and differentiation. 
In summary, the novel regulatory pathway described herein 
for cPGI2 may be relevant o an intracrine effect of PGI2 
generated from arachidonic acid in preadipose cells [5,6]. 
This gene effect might implicate PPARs. If this were so, like 
some members of the steroid hormone receptor family re- 
ported to be phosphoproteins [38], a control of the phosphor- 
ylation state and activity of PPARs in response to prostacy- 
clin could be postulated in preadipose cells. 
Acknowledgements: The authors wish to thank Drs. M.D. Lane (Bal- 
timore, MD, USA) and K.R. Lynch (Charlottesville, VA, USA) for 
their kind gift of a-FABP and AT cDNA, respectively. Drs. I. Safo- 
nova and C. Darimont are greatly acknowledged for stimulating dis- 
cussions, and Mrs. M.T. Ravier and G. Oillaux for expert technical 
and secretarial assistance, respectively. This work was supported by 
CNRS (UMR 134) and Association pour la Recherche sur le Cancer 
(ARC No. 6304). 
References 
[1] Ailhaud, G., Grimaldi, P. and N6grel, R. (1992) Annu. Rev. 
Nutr. 12, 207-233. 
[2] N6grel, R., Galliard, D. and Ailhaud, G. (1989) Biochem. J. 257, 
399-405. 
[3] Catalioto, R.M., Gaillard, D., Maclouf, J., Ailhaud, G. and N6- 
grel, R. (1991) Biochim. Biophys. Acta 1091, 364-369. 
121 
[4] Vassaux, G., Gaillard, D., Ailhaud, G. and N~grel, R. (1992) 
J. Biol. Chem 267, 11092-11097. 
[5] N6grel, R. and Ailhaud, G. (1981) Biochem. Biophys. Res. Com- 
mun. 98, 768-777. 
[6] Hyman, B., Stoll, L. and Spector, A. (1982) Biochim. Biophys. 
Acta 713, 375-385. 
[7] Axelrod, L. and Levine, L. (1981) Diabetes 30, 163-167. 
[8] Richelsen, B. (1987) Biochem. J. 247, 389 394. 
[9] Clesson, H.E. (1980) Biochim. Biophys. Acta 618, 399-406. 
[10] Vassaux, G., Farahi Far, D., Gaillard, D., Ailhaud, G. and N6- 
grel, R. (1993) Prostaglandins 46, 441-451. 
[11] Vassaux, G., N6grel, R., Ailhaud, G. and Gaillard, D. (1994) 
J. Cell Physiol. 161,249-256. 
[12] Gaillard, D., Wabitsch, M., Pipy, B. and N~grel, R. (1991) 
J. Lipid Res. 32, 569-579. 
[13] Darimont, C., Vassaux, G., Ailhaud, G. and N~grel, R. (1994) 
Endocrinology 135, 2030-2036. 
[14] Darimont, C., Vassaux, G., Gaillard, D., Ailhaud, G. and N6- 
grel, R. (1994) Int. J. Obes. 18, 783-788. 
[15] Vassaux, G., Gaillard, G., Darimont, C., Ailhaud, G. and N6- 
grel, R. (1992) Endocrinology 131, 2393-2398. 
[16] Tontonoz, P., Hu, E. and Spiegelman, B.M. (1994) Cell 79, 1147- 
1156. 
[17] Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, 
B.M. and Evans, R.M. (1995) Cell 83, 803-812. 
[18] Kliewer, S.A., Lenhard, J.M., Willson, T.M., Patel, I., Morris, 
D.C. and Lehmann, J.M. (1995) Cell 83, 813 819. 
[19] Braissant, O., FoufeUe, F., Scotto, C., Dauca, M. and Wahli, W. 
(1996) Endocrinology 137, 354-366. 
[20] Yu, K., Bayona, W., Kallen, C.B., Harding, H.P., Ravera, C.P., 
McMahon, G., Brown, M. and Lazar, M.A. (1995) J. Biol. 
Chem. 270, 23975-23983. 
[21] Hertz, R., Berman, I., Keppler, D. and Bar-Tana, J. (1996) Eur. 
J. Biochem. 235, 242-247. 
[22] Brun, R.P., Tontonoz, P., Forman, B.M., Ellis, R., Chen, J., 
Evans, R.M. and Spiegelman, B.M. (1996) Genes Dev. 10, 
974-984. 
[23] Gaillard, D., Poli, P. and N6grel, R. (1985) Exp. Cell Res. 156, 
513-527. 
[24] Green, H. and Kehinde, O. (1979) J. Cell. Physiol. 101, 169 172 
[25] Tavassoli, M. (1982) Exp. Cell Res. 137, 55-62 
[26] Amri, E.Z., Ailhaud, G. and Grimaldi, P. (1991) J. Lipid Res. 32, 
1457-1463. 
[27] Amri, E.Z., Bonino, F., Ailhaud, G., Abumrad, N.A. and Gri- 
maldi, P. (1995) J. Biol. Chem. 270, 2367-2371. 
[28] Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. and Spiegel- 
man, B.M. (1994) Genes Dev. 8, 1224--1234. 
[29] N6grel, R., Grimaldi, P. and Ailhaud, G. (1978) Proc. Natl. 
Acad. Sci. USA 75, 6054-6058. 
[30] Green, H. and Kehinde, O. (1976) Cell 7, 105-113. 
[31] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156- 
159. 
[32] Sealey, J. and Laragh, J. (1977) Cardiovasc. Med. 2, 1079 1092, 
[33] Jacobsen, J. and Poulsen, K. (1985) J. Hypertens. 3, 155 157. 
[34] Dutta-Roy, A. and Sinha, A. (1987) J. Biol. Chem. 262, 12685- 
12691. 
[35] Berry, C., Griffiths, R., HouR, J., Moore, P. and Taylor, G. 
(1986) Br. J. Pharmac. 87, 327 335. 
[36] Coleman, R.A., Smith, W.U and Narumiya, S. (1994) Pharma- 
col. Rev. 46, 205-229. 
[37] Namba, T., Oida, H., Sugimoto, Y., Kakizuka, A., Negishi, M., 
Ichikawa, A. and Narumiya, S. (1994) J. Biol. Chem. 269, 9986- 
9992. 
[38] Kuiper, G.GJ.M. and Brinkmann, A.O. (1994) Mol. Cell. En- 
docrinol. 100, 103 107. 
